Home / Petrochemicals / Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2017

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2017

Published: Dec 2017 | No Of Pages: 198 | Published By: GlobalData

GlobalData's clinical trial report, “Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2017" provides an overview of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Allergan Plc

Merck & Co Inc

Pfizer Inc

Wockhardt Ltd

GlaxoSmithKline Plc

AstraZeneca Plc

LegoChem Biosciences Inc

TaiGen Biopharmaceuticals Holdings Ltd

Pharmaceutical Product Development LLC

KYORIN Holdings Inc

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Five Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials 35

Prominent Drugs 37

Latest Clinical Trials News on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 39

Nov 01, 2017: Novoclem presents promising new data at the North America Cystic Fibrosis Conference 2017 39

Oct 25, 2017: Alopexx completes first-in-man trial of its novel, broad-spectrum anti-microbial vaccine 39

Oct 04, 2017: Allergan To Present New Data on AVYCAZ At IDWeek 2017 In San Diego 40

Oct 04, 2017: Allergan To Present New Data on TEFLARO At IDWeek 2017 In San Diego 40

Oct 04, 2017: Allergan To Present Data on DALVANCE At IDWeek 2017 In San Diego 41

Clinical Trial Profile Snapshots 43

Appendix 195

Abbreviations 195

Definitions 195

Research Methodology 196

Secondary Research 196

About GlobalData 197

Contact Us 197

Source 198

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region, 2017* 8

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries, 2017* 14

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16

Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase, 2017* 26

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region (%), 2017* 8

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16

Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

GlobalData Methodology 196

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +